BMS, Moffitt in Immuno-Oncology Initiative

Bristol-Myers Squibb and Moffitt Cancer Center have entered into a collaboration agreement as part of BMS’ Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a multi-institutional initiative focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
 
BMS and Moffitt will conduct a range of early phase clinical studies, including clinical investigations by young investigators to strengthen their development as clinical research scientists.
 
“Moffitt Cancer Center has had a long-standing commitment to immuno-oncology research, including in partnership with Bristol-Myers Squibb, and we look forward to our continued work with them as part of the I-O RPM program,” said Laura Bessen, MD, head of U.S. Medical, BMS.
 
“This new partnership with Bristol-Myers Squibb will foster new Moffitt investigator-initiated studies for rare tumors and gives our faculty the opportunity to educate research students about innovative clinical trials,” said Dan Sullivan, M.D., Associate Center Director for Clinical Science at Moffitt.